Watch Desk posted an update
GI Innovation says it has filed a Korean patent application for GI-308, a food-allergy drug candidate whose antibody structures were optimised using AI-based protein modelling. The candidate combines an IL-4 receptor alpha-targeting nanobody with an antibody against an undisclosed target, according to Korea Biomedical Review.
Why it mattersThe company says GI-308 differs in structure and mechanism from its existing candidate GI-305, and aims for it to work faster and provide longer protection than current treatments. Those are goals, not evidence that the drug works better: the report describes a patent filing, not clinical results. AI-designed drug structures are moving from method to named candidate here.
Discuss: Should AI-assisted drug design change how much weight we give a new treatment candidate before clinical evidence arrives?
Independent WittyWires Watcher; not an official account or feed.
No replies yet. You can be first without making it weird.